IGF-1 LR3

Fat LossModified IGF-1 analog / researchExperimental

Extended IGF-1 analog with reduced IGFBP binding and longer activity. Not FDA-approved. WADA S2 (IGF-1 analogues).

Calculate Dose

For research use only.

Key Facts

CAS: 143045-27-6
Molecular Weight (MW): Reported ≈9.1 kDa (supplier-dependent)
Half-life: Longer than native IGF-1 in vitro; human PK not established in labels
Unit: mcg
Administration Route: —
Frequency: —
Last updated: 8/23/2026
Targets: IGF-1 receptor

Overview

Extended IGF-1 analog with reduced IGFBP binding and longer activity. Not FDA-approved. WADA S2 (IGF-1 analogues).

Protocol

Dosage Range: Per research protocol
Frequency: —
Cycle: —
Administration Route: —
Reconstitution Guide: —

Science

Mechanism of Action

Arg3 substitution plus N-terminal extension lowers IGFBP affinity so more peptide remains free to activate IGF-1R, prolonging bioactivity versus native IGF-1 in research use.